DK2144905T3 - Terapeutiske midler - Google Patents

Terapeutiske midler

Info

Publication number
DK2144905T3
DK2144905T3 DK08742520.3T DK08742520T DK2144905T3 DK 2144905 T3 DK2144905 T3 DK 2144905T3 DK 08742520 T DK08742520 T DK 08742520T DK 2144905 T3 DK2144905 T3 DK 2144905T3
Authority
DK
Denmark
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Application number
DK08742520.3T
Other languages
English (en)
Inventor
Mark T Bilodeau
Kausik K Nanda
Wesley B Trotter
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39540659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2144905(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2144905T3 publication Critical patent/DK2144905T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DK08742520.3T 2007-04-04 2008-04-03 Terapeutiske midler DK2144905T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92175907P 2007-04-04 2007-04-04
PCT/US2008/004336 WO2008124030A1 (en) 2007-04-04 2008-04-03 Therapeutic agents

Publications (1)

Publication Number Publication Date
DK2144905T3 true DK2144905T3 (da) 2013-03-11

Family

ID=39540659

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08742520.3T DK2144905T3 (da) 2007-04-04 2008-04-03 Terapeutiske midler

Country Status (33)

Country Link
US (3) US8252799B2 (da)
EP (1) EP2144905B1 (da)
JP (2) JP5097265B2 (da)
KR (1) KR101562835B1 (da)
CN (1) CN101675046B (da)
AU (1) AU2008236705B2 (da)
BR (1) BRPI0809492A2 (da)
CA (1) CA2682494C (da)
CO (1) CO6300938A2 (da)
CR (1) CR11047A (da)
CY (1) CY1113649T1 (da)
DK (1) DK2144905T3 (da)
DO (1) DOP2009000232A (da)
EC (1) ECSP099674A (da)
ES (1) ES2398312T3 (da)
GT (1) GT200900258A (da)
HK (1) HK1134291A1 (da)
HR (1) HRP20130041T8 (da)
IL (1) IL201235A (da)
MA (1) MA31323B1 (da)
MX (1) MX2009010678A (da)
MY (1) MY153868A (da)
NI (1) NI200900175A (da)
NZ (1) NZ580167A (da)
PL (1) PL2144905T3 (da)
PT (1) PT2144905E (da)
RS (1) RS52661B (da)
RU (1) RU2468025C2 (da)
SI (1) SI2144905T1 (da)
SV (1) SV2009003380A (da)
UA (1) UA96015C2 (da)
WO (1) WO2008124030A1 (da)
ZA (1) ZA200906525B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032987A (ja) * 1998-07-16 2000-02-02 Dai Ichi Seiyaku Co Ltd Ｄｎａ
ES2326078T3 (es) 2002-08-22 2009-09-30 Dainippon Sumitomo Pharma Co., Ltd. Medicamento destinado al sindrome de la disfuncion de integracion.
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
JP5097265B2 (ja) 2007-04-04 2012-12-12 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US20110124659A1 (en) * 2009-11-17 2011-05-26 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP2685979B1 (en) 2011-03-18 2016-08-24 Alkermes Pharma Ireland Limited Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN103207246B (zh) * 2012-12-21 2017-10-10 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
PL3344273T3 (pl) 2015-08-31 2020-06-01 Nutramax Laboratories, Inc. Kompozycje zawierające magnolię, korkowiec, teaninę i/lub białko serwatkowe
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
IT1242929B (it) * 1990-11-07 1994-05-18 Nordica Spa Struttura di leva per calzature sportive, particolarmente per scarponi da sci
WO1996014297A1 (fr) * 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de lactame
JP3775823B2 (ja) * 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
CA2394548A1 (en) * 1999-12-17 2001-06-21 Joseph P. Yevich Antipsychotic heterocycle compounds
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
ATE543817T1 (de) 2003-07-29 2012-02-15 Dainippon Sumitomo Pharma Co Verfahren zur herstellung einer imidverbindung
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
JP5097265B2 (ja) 2007-04-04 2012-12-12 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US20090076027A1 (en) 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20110003994A1 (en) 2009-07-02 2011-01-06 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative

Also Published As

Publication number Publication date
US9867821B2 (en) 2018-01-16
UA96015C2 (en) 2011-09-26
NZ580167A (en) 2012-02-24
GT200900258A (es) 2011-10-18
PT2144905E (pt) 2013-02-26
JP5686780B2 (ja) 2015-03-18
US20100105697A1 (en) 2010-04-29
US20120316181A1 (en) 2012-12-13
JP2010523567A (ja) 2010-07-15
RS52661B (en) 2013-06-28
US8252799B2 (en) 2012-08-28
HRP20130041T1 (hr) 2013-02-28
CR11047A (es) 2009-10-23
RU2009136592A (ru) 2011-04-20
AU2008236705A1 (en) 2008-10-16
CN101675046B (zh) 2013-02-06
AU2008236705B2 (en) 2014-01-23
MA31323B1 (fr) 2010-04-01
HRP20130041T8 (en) 2013-03-31
KR101562835B1 (ko) 2015-10-23
EP2144905A1 (en) 2010-01-20
EP2144905B1 (en) 2012-11-28
US8410111B2 (en) 2013-04-02
WO2008124030A1 (en) 2008-10-16
ZA200906525B (en) 2010-04-28
NI200900175A (es) 2010-09-07
SV2009003380A (es) 2010-04-13
HK1134291A1 (en) 2010-04-23
CA2682494C (en) 2011-10-11
CO6300938A2 (es) 2011-07-21
IL201235A0 (en) 2010-05-31
US20130178481A1 (en) 2013-07-11
PL2144905T3 (pl) 2013-04-30
KR20090127416A (ko) 2009-12-11
CY1113649T1 (el) 2016-10-05
BRPI0809492A2 (pt) 2014-09-23
CA2682494A1 (en) 2008-10-16
SI2144905T1 (sl) 2013-03-29
ES2398312T3 (es) 2013-03-15
JP2013028626A (ja) 2013-02-07
DOP2009000232A (es) 2016-11-15
MY153868A (en) 2015-03-30
MX2009010678A (es) 2009-10-23
IL201235A (en) 2013-12-31
CN101675046A (zh) 2010-03-17
ECSP099674A (es) 2009-11-30
JP5097265B2 (ja) 2012-12-12
RU2468025C2 (ru) 2012-11-27

Similar Documents

Publication Publication Date Title
LTPA2018006I1 (lt) Pakeistųjų oksazolidinonų kombinuota terapija
BRPI0916931A2 (pt) agentes terapêuticos
DK2144905T3 (da) Terapeutiske midler
BRPI0807137A2 (pt) Agentes antiparasitários
ATE443753T1 (de) Nuancierungsmittel
DK2035369T3 (da) Terapeutiske
EP2117311A4 (en) THERAPEUTICS
DK2178568T3 (da) Kontrastmidler
DK2185142T3 (da) Antiseptiske midler
GB0723747D0 (en) Therapeutic agents
DK2173831T3 (da) Brøndbehandling
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
SMT201600041B (it) Agenti terapeutici 713
BRPI0716742A2 (pt) Lactamas terapêuticas
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0906879A2 (pt) Compostos terapêuticos
GB0723748D0 (en) Therapeutic agents
DK2257548T3 (da) Terapeutiske forbindelser
ES1066260Y (es) Bañera
TH107071B (th) อ่างอาบน้ำ
TH102199B (th) อ่างอาบน้ำ
TH107066B (th) อ่างอาบน้ำ
TH107068B (th) อ่างอาบน้ำ